Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study

Archives of Neurology

Volumn 57, Issue 4, 2000, Pages 470-475

  Rinne, Juha O ^a   Portin, Raija ^a   Ruottinen, Hanna ^a   Nurmi, Elina ^a   Bergman, Jörgen ^b   Haaparanta, Merja ^b   Solin, Olof ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18;

ADULT; AGED; ARTICLE; ATTENTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; HUMAN; MALE; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0034037276     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.4.470     Document Type: Article

References (52)

1. Robbins TW, James M, Owen AM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe function. J Neurol Neurosurg Psychiatry. 1994;57:79-88.
2. Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease and Alzheimer's disease. Neurology. 1986;36:1179-1185.
3. Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer's, Huntington's and Parkinson's disease. Arch Neurol. 1993;50:374-379.
4. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain. 1986;109:845-883.
5. Lange KW, Paul GM, Robbins TW, Marsden CD. L-dopa and frontal cognitive function in Parkinson's disease. Adv Neurol. 1993;60:475-478.
6. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 1983;106:252-270.
7. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991;114:2095-2122.
8. Cummings JL. Subcortical dementia: neuropsychology, neuropsychiatry and pathophysiology. Br J Psychiatry. 1986;149:682-697
9. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci. 1986;9:357-381.
10. Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 1991; 14:21-27.
11. Gaspar P, Stepniewska I, Kaas JH. Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol. 1992;325:1-21.
12. Gingrich JA, Caron M. Recent advances in the molecular biology of dopamine receptors. Ann Rev Neurosci. 1993;16:299-321
13. Bhatia KP, Marsden CO. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117:859-876.
14. Bernheimer H, Birkmeyer W, Hornykiewicz O, et al. Brain dopamine and the syndrome of Parkinson and Huntington. J Neurol Sci. 1973;20:415-423.
15. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Ann Neurol. 1990;113:1539-1552.
16. Rinne JO, Rummukainen J, Paljärvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol. 1989; 26:47-50.
17. Scatton B, Javoy-Agid F, Rouquier F, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983;275:321-328.
18. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain. 1988;111:299-321.
19. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 1992;107:394-404.
20. Yanagisawa N. Historical review of research on functions of basal ganglia. Eur Neurol. 1996;36(suppl 1):2-8.
21. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of the patients for clinicians. J Psychiatr Res. 1975; 12:189-198.
23. Kujala P, Portin R, Revonsuo A, Ruutiainen J. Automatic and controlled information processing in multiple sclerosis. Brain. 1994;117:1115-1126.
24. Kujala P, Portin R, Revonsuo A, Ruutiainen J. Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995;59:77-82.
25. Wechsler D. Manual for Wechsler Adult Intelligence Scale. New York, NY: Psychological Corp; 1955.
26. Benton AL. The Revised Visual Retention Test. New York, NY: Psychological Corp: 1963.
27. Portin R, Rinne UK. Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's Disease: Current Progress, Problems and Management. Amsterdam, the Netherlands: Elsevier Biomedical Press; 1980:271-304.
28. Revonsuo A, Portin R, Koivikko L, Rinne JO, Rinne UK. Slowing of information processing in Parkinson's disease. Brain Cogn. 1993;21:87-110.
29. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935; 18:643-662.
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
31. Ruottinen HM, Rinne JO, Haaparanta M, et al. [18F]Fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psychiatry. 1997;62:622-625.
32. 3COOF: a high yield synthesis of 6-[18F]fluoro-L-dopa. Appl Radiat Isot. 1992;43:989-996.
33. Bergman J, Haaparanta M, Lehikoinen P, Solin O. Electrophilic synthesis of 6-[18F]fluoro-L-dopa, starting from aqueous [18F]fluorine. J Labelled Compounds Radiopharm. 1994;35:476-477.
34. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
35. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with [18F]dopa and positron emission tomography. Neurology. 1992;42:1894-1900.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
37. Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36:176-182.
38. Holthoff-Detto VA, Kessler J, Herholz K, et al. Functional effects of striatal dysfunction in Parkinson's disease. Arch Neurol. 1997;54:145-150.
39. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380-1386.
40. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991;50:743-755.
41. Stern Y, Langston JW. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 1985;35:1506-1509.
42. Stern Y, Tetrud JW, Martin WRW, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology. 1990;40:261-264.
43. Hietanen M, Teräväinen H. Cognitive performance in early Parkinson's disease. Acta Neurol Scand. 1986;37:151-159.
44. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord. 1990;5:203-213.
45. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J Nucl Med. 1996;37:1115-1122.
46. Karbe H, Holthoff V, Huber M, et al. Positron emission tomography in degenerative disorders of tbe dopaminergic system. J Neural Transm. 1992;4:121-130.
47. Turjanski N, Brooks DJ. PET and the investigation of dementia in the parkinsonian patient. J Neural Transm. 1997;51(suppl):37-48.
48. Schapiro MB, Crady C, Ball MJ, et al. Reductions in parietal/temporal cerebral glucose metabolism are not specific for Alzheimer's disease. Neurology. 1990; 40(suppl 1):152.
49. Brucke T, Asenbaum S, Pozzera A, et al. Dopaminergic nerve cell loss in Parkinson's disease quantified with [I-123] β-CIT and SPECT correlates with clinical findings. Mov Disord. 1994;9(suppl 1):120.
50. Rinne JO, Kuikka JT, Bergström K, Rinne UK. Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [123I] β-CIT SPECT. Parkinsonism Related Disord. 1995;1:47-52.
51. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I] β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589-598.
52. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-β CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37:1760-1765.